Nathwani Dilip, Li Jim Z, Balan Dan A, Willke Richard J, Rittenhouse Brian E, Mozaffari Essy, Tavakoli Manouche, Tang Tom
Infection and Immunodeficiency Unit, Ward 42, East Block, Ninewells Hospital and Medical School, Tayside University Hospitals, Dundee, Scotland DD1 9SY, UK.
Int J Antimicrob Agents. 2004 Apr;23(4):315-24. doi: 10.1016/j.ijantimicag.2003.09.020.
In a recent multinational trial, hospital resource use and total cost of treatment were compared between linezolid and teicoplanin for severe Gram-positive bacterial infections among 227 European hospitalised patients. The results show that the linezolid group had a 3.2-day (6.3 for linezolid versus 9.5 for teicoplanin groups) shorter mean intravenous antibiotic treatment duration. Certain baseline variables, particularly the inpatient location at enrolment and the presence of outpatient/home parenteral antibiotic therapy (OHPAT), had substantial effects on length of stay (LOS) and cost of treatment. After adjusting for the between-treatment difference in these two variables and other baseline variables, the results showed non-significant shorter LOS and lower mean total cost of treatment for the linezolid group among patients with no access to OHPAT.
在最近一项跨国试验中，对227名欧洲住院患者中，利奈唑胺和替考拉宁用于治疗严重革兰氏阳性菌感染时的医院资源使用情况和总治疗成本进行了比较。结果显示，利奈唑胺组的平均静脉用抗生素治疗持续时间缩短了3.2天（利奈唑胺组为6.3天，替考拉宁组为9.5天）。某些基线变量，特别是入组时的住院地点以及门诊/家庭肠外抗生素治疗（OHPAT）的情况，对住院时间（LOS）和治疗成本有重大影响。在对这两个变量以及其他基线变量的治疗间差异进行调整后，结果显示，在无法接受OHPAT的患者中，利奈唑胺组的住院时间虽有缩短但无统计学意义，且平均总治疗成本较低。
